Disclosed herein is the use of an effective amount of an effective amount of a TOR kinase inhibitor represented by structural formula (I) and an effective amount of a 5-Substituted Quinazolinone Compound in the manufacture of a medicament for treating or preventing cancer, particularly a liver cancer or a blood borne cancer which includes a lymphoma, a leukemia or a mutliple myeloma, wherein the variables shown in formula (I) are as defined in the specification. The preferred TOR kinase inhibitor is 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropyrazino-[2,3-b]pyrazin-2(1H)-one or 1-ethyl-7-(2-methyl-6-(4H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one.
